If you have osteoporosis, you should be getting treated. If you have low bone mass, or risk for osteoporosis you can consider diet, exercise and what physicians call "watchful waiting." In the days when women took estrogen, mostly for other reasons, they were also protected from hip fractures. Now with women stopping estrogen, a large study published in Menopause at the end of 2011, it shows that just discontinuing your medication lead to a 55% greater risk of hip fractures. If you look at what the bone mass did, for women on estrogen who had normal to low scores, about 2 years out the average patient had slipped into osteoporosis. But when you think about treating your bones with other medications, we also have to think about the long term consequences of those medications. The most common is to get a prescription of bisphosphonate. In looking over the over 300 reports of odd fractures in users of bisphosphonates a task force of ASBMR, a bone research group, had come out with a set of recommendations in early 2011, most of which as of 2012, considered the standards you can discuss with your gyno, they are as listed here:
- Restrict the long-term use of potent antiresorptive agents to patients with osteoporosis or high fracture risk, and avoid their use in patients with low bone mass (osteopenia) without other risk factors who are at low risk of fracture.
- Do not combine bisphosphonates or denosumab with estrogens or estrogen agonist/antagonists (formerly known as SERMs) without documentation of inadequate response to estrogens or estrogen or estrogen agonist/antagonists.
- Be prepared to explain to patients who are candidates for bisphosphonate therapy that the likelihood of having a hip or spine fracture is much greater if they do NOT take therapy than is the risk of having an atpical fracture on treatment, especially during the first 5 years.
- Similarly, encourage high-risk patients NOT to discontinue bisphosphonate therapy on the basis of the media coverage of atypical fractures, for the fracture-protective effect of therapy disappears upon stopping treatment, just as it does when estrogen therapy is withdrawn.
- At annual follow-up visits, reevaluate the justification for bisphosphonate therapy and remind those continuing treatment to report the occurrence of thigh pain so that affected patients can be identified and managed before frank femoral fracture occurs
Comments
Post a Comment
Thank you for your comments and questions. WE hope you will buy our book, https://www.gynogab.com/shop This blog is not intended to replace medical care, but is informational only. We hope you will become a follower or visit Womens Health Practice. We offer a variety of unique services including MonaLisa Touch, Coolsculpting, Labiaplasty, and Gynecoloigic Clinical Research Trials. For more information on menopause see